Bristol-Myers Squibb Seen Beating Q3 Revenue Estimates, RBC Says

10:53 AM EDT, 10/19/2026 (MT Newswires) -- Bristol-Myers Squibb (BMY) is expected to beat consensus Q3 revenue estimates, driven by stronger-than-expected sales of legacy products Eliquis and Revlimid, as well as growth products including Breyanzi and Reblozyl, RBC Capital Markets analysts said in a Monday note. The company is scheduled to report its Q3 financial results on Oct. 29. RBC said crucial upcoming catalysts for the stock include phase-3 readouts for milvexian in stroke prevention and atrial fibrillation, and another phase-3 trial looking into Sotyktu in systemic lupus erythematosus. Analysts said that commentary and confidence in the Milvexian data, as well as color on recent admilparant data, will be important for sentiment. RBC maintained a Sector Perform rating and a $64 price target on the stock. Price: 59.15, Change: -0.60, Percent Change: -1.00